How to read an initial pediatric study plan

PREA requires a pediatric assessment before certain drug and biologic applications can move forward — a requirement covered in what the Pediatric Research Equity Act requires. What that piece doesn’t cover is the filing that comes first: before any pediatric study happens, the sponsor and FDA have to agree on a plan for what the eventual assessment will look like. That plan is the initial Pediatric Study Plan, or iPSP, and treating it as a formality rather than a negotiation is the most common way sponsors lose the lead time it’s meant to buy them.

The plan comes before the studies, not after

It’s easy to read “pediatric study plan” and assume it describes the studies themselves. It doesn’t. The iPSP is the document that forces the decisions a pediatric program needs before any protocol gets written: which pediatric subpopulations the product will be studied in, what studies or nonclinical approaches are planned for each one, what waivers or deferrals the sponsor intends to request, and how the whole plan lines up against the timeline for the adult development program it’s attached to. Submitting it late, or treating it as a cover sheet rather than a real planning document, doesn’t just risk a slow FDA response — it means the pediatric program gets designed after decisions that should have shaped it are already locked in on the adult side.

Waivers and deferrals get negotiated inside the iPSP, not around it

FDA’s Pediatric Review Committee (PeRC) reviews iPSPs, along with the waivers and deferrals sponsors request inside them, for consistency across CDER and CBER. A full waiver removes the pediatric-assessment obligation entirely — FDA grants one when the studies would be impossible or highly impracticable, among other grounds. A deferral doesn’t remove the obligation; it postpones it, often because the adult data already support approval while the pediatric studies are still running. Both requests get made and argued inside the iPSP process, not as a side conversation after the plan is agreed. If FDA and the sponsor can’t reach agreement, FDA issues correspondence documenting the disagreement — and that correspondence, not silence, is what has to accompany the eventual marketing application if an agreed plan was never reached.

The iPSP is easy to underweight precisely because it produces no data of its own — just an agreement about what data will eventually get produced. Treat that agreement with the seriousness of the studies it governs, and the pediatric program it sets up has a much better chance of landing on time. How to estimate a regulatory submission timeline covers the broader planning discipline this fits into, and how to read an IND application covers where the clinical program the iPSP eventually feeds into gets built.